Cargando…
The dark side of immunotherapy
Immunotherapy has broadened the therapeutic scope and response for many cancer patients with drugs that are generally of higher efficacy and less toxicity than prior therapies. Multiple classes of immunotherapies such as targeted antibodies and immune checkpoint inhibitors (ICI), cell-based immunoth...
Autores principales: | Okwundu, Nwanneka, Grossman, Douglas, Hu-Lieskovan, Siwen, Grossmann, Kenneth F., Swami, Umang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8267325/ https://www.ncbi.nlm.nih.gov/pubmed/34277841 http://dx.doi.org/10.21037/atm-20-4750 |
Ejemplares similares
-
Cancer immunotherapy: recent advances and challenges
por: Swami, Umang, et al.
Publicado: (2021) -
Current status of intralesional agents in treatment of malignant melanoma
por: Zawit, Misam, et al.
Publicado: (2021) -
Real-world experience with elective discontinuation of PD-1 inhibitors at 1 year in patients with metastatic melanoma
por: Pokorny, Rebecca, et al.
Publicado: (2021) -
Safety of immune checkpoint inhibitors in patients with cancer and pre-existing autoimmune disease
por: Alexander, Swetha, et al.
Publicado: (2021) -
Turning ‘Cold’ tumors ‘Hot’: immunotherapies in sarcoma
por: Rytlewski, Jeff, et al.
Publicado: (2021)